Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

• This invention relates to a novel method of prolonging the release of a drug from a solid carrier. More particularly, the invention relates to the vapor treatment of a drug composition dispersed in a plastic carrier. This treatment fuses the individual particles of plastic into a continuous network of plastic which impedes the release of the drug from the carrier when such a composition is administered orally.
• enteric coatings have been applied for many years to a wide variety of drugs in an attempt to protect the drug from gastric secretions, or to protect the stomach from the harsh effect of the drug.
• Enteric coatings have employed many kinds of materials and all are designed to be resistant to gastric secretions, but must be readily disintegrated in the intestinal tract in order for the drug to become effective.
• the enteric coating is designed to prevent release of drug in the stomach and to be destroyed or broken up in the intestinal tract.
• Enteric cOatings as a class depend upon some type of chemical action or reaction for their disintegration.
• time-disintegration coatings Another class of protective coating for encompassaments is the type known as time-disintegration coatings.
• time-disintegration coatings a class of materials is used which is dissolved or distinguished slowly as the tablet passes through the stomach and intestine, and an amount of coating is used which is designed to allow release of the drug after a certain period of time in the body. Due to the tremendous differences in the operation of the gastrointestinal mechanism in different persons the time-disintegration coating does not work the same way in every person but rather is designed to give results based on averages.
• a variation of the time-disintegration dosage form just described is one in which particles of a medicament are coated with a varying number of layers of a material which will be slowly washed away or destroyed by the gastro-intestinal fluids.
• a portion of the drug has little or no coating for initial response, thin coatings are used for a quick follow-up response and thicker coatings are used for a delayed response.
• Time-disintegration coatings as a class depend for their disintegration upon the effects of agents found in the gastro-intest-inal fluids.
• the enzymes, fat-solubilizers and emulsifiersin these fluids hasten the breaking-up or wearing-away of the coatings.
• Another object of the invention is to provide a method for the vapor treatment of a drug composition dispersed in a plastic carrier which will coalesce the individual particles of plastic to impede the release of the drug when such a composition is orally administered.
• a further object of the invention is to provide a method for the preparation of an oral dosage form from which the drug will be slowly released by a substantially physical process of dissolving drug out of a solid, inert body independently of the digestive process.
• the method consists of exposing a compressed mixture (conveniently in table form) of drug and plastic to the vapors of a volatile organic solvent for the plastic in a confined space for a period of time suflicient to result in softening of the surface of said plastic.
• Suitable solvents include methylene chloride, ethyl acetate, ethylene dichloride and toluene.
• acetone is employed as the solvent.
• the compressed mixture of drug and plastic is exposed in a confined space at room temperature and atmospheric pressure for a period of from 3 to 24 hours.
• the vapor treatment may be carried out at temperatures of about 100 F. at atmospheric pressure or at considerably higher temperatures and under vacuum.
• the plastic particles Upon drying the treated tablet, the plastic particles adhere to one another more firmly forming a porous body having a network of continuous interstices throughout the tablet.
• the plastic body resists disintegration during exposure to water.
• plastic particles are so loosely held together that the tablets disintegrate within a very short time.
• the treatment results in a partial solubilization of the individual particles of plastic by the solvent vapor and a fusion of one particle of plastic to another.
• the drug is leached or diffused out of the plastic body.
• the amount of drug released in the early stages of the leaching process is sufficient to provide the desired initial pharmacologic response and the amount of drug released thereafter will sustain the pharmacologic response over an extended period of time. Because the releasing action is entirely physical, rather than chemical, the results are readily predictable.
• drug is used herein in its broadest sense as indicating any substance or composition which will give a pharmacologic response.
• water soluble it is meant to indicate that the drug must be soluble in aqueous liquids to at least a certain small extent but drugs which are readily soluble in water will, of course, make up the preferred group.
• Methamphetamine salts hexocyclium methylsulfate, paraamino benzoic acid, ephedrine, mannitol hexanitrate, amphetamine, erythromycin salts, penicillin salts, pentobarbital, phenobarbital, atropine, belladonna, theophylline, sex hormones, hydantoins, trimethadione, watersoluble vitamins such as B and C, benzazoline, toluidine blue and related drugs are representative of the broad class of drugs which may be incorporated in compositions suitable for treatment by this new method.
• the plastics to which this invention pertains may be any synthetic resinous of polymeric material which is substantially inert to gastro-intestinal liquids and which, of course, is essentially non-toxic and can be ingested without danger.
• the plastic mass or body may be referred to as an orally ingestible plastic carrier, in which the drug is dispersed. It is desirable that the drug be uniformly dispersed throughout the body or mass of the carrier in order that uniformity of results may be obtained.
• the polymers suitable for use in this invention must be resistant to flow, sintering or blocking at temperatures likely to be encountered in storage. While rubbery materials can be used, the manufacture of the finished product is easier if the polymer is hard, i.e., in a glassy or crystalline state at ambient temperature. Since the temperature at Which pharmaceutical products may be stored may rise as high as 105 F., the glass point of a suitable polymer should preferably be not much lower than 105 F. The glass point is defined in Flory, Principles of Polymer Chemistry, p. 56, Cornell University Press, 1953. Briefly, it is the midpoint of the narrow temperature region above which an amorphous polymer exists in a viscous or rubbery condition and below which it is hard and relatively brittle.
• polymers and copolymers which can be used successfully in this invention as will be evident to those skilled in the art.
• a few examples are polyethylene, polymethylmethacrylate, copolymers of methylmethacrylate and alkyl acrylates, polyvinylacetate, polyhexamethylene adipamide and the like.
• the polymers can be prepared by bulk, solution, suspension, or emulsion polymerization. If the last method is used, the polymer may be coagulated into solid particles which can be readily mixed with a drug or a drug may be admixed before coagulation as will be more fully discussed hereinafter.
• composition employed in the method of this invention may be described as having discrete particles of a drug dispersed in a matrix of a plastic carrier.
• This composition is to be distinguished from a plastic tablet coating in which the coating completely surrounds the drug and prevents access of liquids to the drug until the coating is disrupted or destroyed.
• the plastic takes the form of a foraminous body with drug contained in the pockets or voids, but the drug is accessible to liquids and may be removed from the plastic body by a leaching or washing action without materially affecting the phyiscal condition of the plastic body.
• Other water-soluble excipients or adjuvants which may be employed include dextrose, acacia, sucrose, polyethylene glycols, sorbitol, urea, polyvinylpyrrolidone, inositol, lactose, mannitol, methocel, calcium chloride, pectin and the like.
• composition employed in the method of this invention can be made in a number of ways which will be apparent to one skilled in the plastics art.
• One suitable way of making the composition is to thoroughly blend a plastic in powder or granular form with the drug in crystalline or granular form and then subject the mixture to heat and pressure so that the composition is converted into a solid body or mass having the drug dispersed therein. It is possible by the use of selected proportions of particles having different sizes to arrive at any desired rate of diffusion or leaching. This is an important and highly desirable feature since it enables the compounder to adjust the rate of release of the drug to a given set of conditions.
• Another method is to disperse the drug in a liquid monomer, and polymerize the mass, thereby achieving an excellent dispersion of the drug in the plastic, which may then be comminuted to desired size.
• This method may be varied by using mixtures of monomers, and by adding polyfunctional monomers, which result in a cross-linked plastic, insolu-be in most solvents.
• normally water-soluble polymers and very hydrophilic polymers, such as polyacrylic acid may be employed in the invention.
• a drug of limited water solubility may be finely ground and suspended in a latex or aqueous dispersion of an appropriate plastic.
• the latex may then be coagulated by known procedures to give a finely divided crumb in which the plastic and drug are intimately associated.
• a dispersion or solution of a drug in such a latex may be spray dried or drum dried and the solid product ground and screened to give a suitable product.
• the plastic is dissolved in a solvent solution, the drug is dispersed or dissolved therein and the suspension or solution cast as a film by known techniques. The film can be ground and screened to proper size.
• the amount of drug which is suspended or dispersed in the plastic mass may be varied at will from a small but significant amount capable of giving a pharmacologic response up to the saturation point beyond which the composition will no longer have its characteristic properties as a plastic mass. In one instance it was found that up to by weight of drug based on the total weight of the composition can be employed. It will be apparent that the concentration of the drug, the particle size of the composition and the water permeability of the plastic mass provide a great deal of control over the response of the drug and may be interrelated in such a way as to give the compounder great leeway in the preparation of tailored compositions.
• composition employed in the vapor treatment method of this invention may be prepared by grinding or otherwise comminuting the plastic mass having the drug embedded therein to a desired particle size or range of particle sizes and mixing, combining or incorporating in a pharmaceutical carrier.
• Particle size in an important aspect of the invention since the rate of diffusion or leaching out of the drug from a given plastic after vapor treatment will be slower from a small particle than from a large particle.
• the particles may be recombined with tableting adjuvants in the form of conventional pharmaceutical tablets.
• Example I Mg. Sodium p-aminobenzoate 8.26 Sodium chloride 24.80
• the plastic body is com-
• another p r compressed tablets were p pletely intact as a single entity at the end of the leaching pared 111 a manner Wherem the amouhls of process each component are given below on a per tablet basis:
• Example II Compressed tablets wherein all ingredients and amounts Methamphetamine hydrochloride 5 are on a per tablet basis were prepared in the normal Polyvmylpyrrohdone 26-41 manner; Methylacrylate-methylmethacrylate copolymer 77.37 M Talc t 5.36 Hexocyclium methylsulfate 7 5 Magnesium stearate Mithylaerylale'methylmethael'ylale P Y 30 These tablets were treated with acetone vapors in a vace uum chamber for 5 hours at a temperature of 30 C. Magnesium stearate 3-3 and a pressure of 240 mm. of mercury.
• the tablets were The tablets were exposed to acetone vapor in a closed then alr-dried overnight and finally oven-dried at 140 F. container for 24 hours at room tempera/[ma The dried for 48 hours to remove all traces of acetone. The treated tablets were then tested for the release of the drug by exggg g ggig gggg g; g: lg f ig 2$ 2g:
• the solvent Talc 13,3 employed is selected from the group consisting of acetone, Magnesium stearate 6,6 methylene chloride, ethyl acetate, ethylene dichloride and toluene.
• the tablets were thereafter subjected to acetone vapors 5.
• the tablets were then air dried and the release of the thetic polymer carrier having a glass point of at least 105' drug from the tablets was determined in vitro by contact- F.
• a method as claimed in claim 5 wherein the drug is selected from the group consisting of hexocyclium methylsulfate, methamphetamine hydrochloride, nicotinic acid, phenobarbital sodium and sodium paraminobenzoate.
• polymer carrier is selected from the group consisting of polyethylene, polyvinylacetate, polymethylmethacrylate and methylacrylate-methylmethacrylate co-polymers.
• the method of prolonging the release of methamphetamine hydrochloride from a non-toxic, inert, water insoluble, non-brittle, synthetic methylacrylate-methylmethacrylate co-polymer which comprises exposing a compressed tablet of said hydrochloride and said c0- polymer to acetone vapors in a vacuum chamber for about 5 hours at a temperature of about 30 C. and a pressure of about 240 millimeters of mercury to fuse the individual particles of co-polymer throughout the tablet into a foraminous structure to further embed the drug therein.
• a method of prolonging the release of hexocyclium methylsulfate from a non-toxic, inert, water insoluble, non-brittle, synthetic methylacrylatemethylmethacrylate co-polymer which comprises exposing a compressed tablet of said sulfate and said co-polymer to acetone vapors in a closed container for about 24 hours at room temperature to fuse the individual particles of co-polymer throughout the tablet into a foraminous structure to further embed the drug therein.
• the method of treating the human body which comprises administering to a human host the product produced by the method of claim 5, said product being 3 adapted to release an efiective amount of drug gradually over a period of time during which the said product is present in the body.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (4)

Applications Claiming Priority (1)

Publications (1)

Family

ID=25122720

Family Applications (1)

Country Status (4)

Cited By (59)

Families Citing this family (2)

Citations (16)

• 1958
  • 1958-12-19 US US781433A patent/US3087860A/en not_active Expired - Lifetime
• 1959
  • 1959-12-04 GB GB41340/59A patent/GB908016A/en not_active Expired
  • 1959-12-09 ES ES0254048A patent/ES254048A1/es not_active Expired
  • 1959-12-11 BE BE585579A patent/BE585579A/fr unknown

Patent Citations (16)

Also Published As

Similar Documents